CD19 and myeloid sarcoma: Two patients with progressive MS who received CD19 CAR-T cell therapy (KYV-101) showed CAR-T cell presence and expansion in the cerebrospinal fluid, without neurotoxicity, alongside a reduction in intrathecal antibodies in one patient (132).